Delirium and its Treatment

Attard, Azizah; Ranjith, Gopinath; Taylor, David
June 2008
CNS Drugs;2008, Vol. 22 Issue 8, p631
Academic Journal
Delirium occurs at rates ranging from 10% to 30% of all hospital admissions. It is a negative prognostic indicator, often leading to longer hospital stays and higher mortality. The aetiology of delirium is multifactorial and many causes have been suggested. The stress-diathesis model, which posits an interaction between the underlying vulnerability and the nature of the precipitating factor, is useful in understanding delirium. Preventing delirium is the most effective strategy for reducing its frequency and complications. Environmental strategies are valuable but are often underutilized, while remedial treatment is usually aimed at specific symptoms of delirium. Antipsychotics are the mainstay of pharmacological treatment and have been shown to be effective in treating symptoms of both hyperactive and hypoactive delirium, as well as generally improving cognition. Haloperidol is considered to be first-line treatment as it can be administered via many routes, has fewer active metabolites, limited anticholinergic effects and has a lower propensity for sedative or hypotensive effects compared with many other antipsychotics. Potential benefits of atypical compared with typical antipsychotics include the lower propensity to cause over-sedation and movement disorder. Of the second-generation antipsychotics investigated in delirium, most data support the use of risperidone and olanzapine. Other drugs (e.g. aripiprazole, quetiapine, donepezil and flumazenil) have been evaluated but data are limited. Benzodiazepines are the drugs of choice (in addition to antipsychotics) for delirium that is not controlled with an antipsychotic (and can be used alone for the treatment of alcohol and sedative hypnotic withdrawal-related delirium). Lorazepam is the benzodiazepine of choice as it has a rapid onset and shorter duration of action, a low risk of accumulation, no major active metabolites and its bioavailability is more predictable when it is administered both orally and intramuscularly.


Related Articles

  • Chiropractic management of musculoskeletal pain secondary to tardive dyskinesia. Schoonderwoerd, Kelly // Journal of the Canadian Chiropractic Association;Jun2005, Vol. 49 Issue 2, p92 

    Tardive dyskinesia (TD) is an umbrella term typically used to describe a movement disorder associated with the use of neuroleptic (anti-psychotic) medication. It is characterized by abnormal, repetitive and involuntary movements. The movements may be around the mouth and face (orofacial...

  • Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities. Friedlander, Robin; Lazar, Susan; Klancnik, Joseph; Friedlander, R; Lazar, S; Klancnik, J // Canadian Journal of Psychiatry;Oct2001, Vol. 46 Issue 8, p741 

    Objective: To study the usage, efficacy, and side effects patterns of atypical neuroleptics (atypicals) in adolescents and young adults with developmental disabilities (DDs) (mental retardation). Method: We undertook a chart review of adolescents and young adults (under...

  • Catastrophic reactions induced by tetrabenazine. Bruneau, Marie-Andrée; Lespérance, Paul; Chouinard, Sylvain; Bruneau, Marie-Andrée; Lespérance, Paul // Canadian Journal of Psychiatry;Sep2002, Vol. 47 Issue 7, p683 

    Describes the cases illustrating psychiatric side effects of tetrabenazine, an antipsychotic drug. Introduction of tetrabenazine in 1956; Treatment of hyperkinetic movement disorders; Absence of risk factors for psychiatric side effects.

  • Biovail acquires rights to develop Santhera's dyskinesia drug.  // PharmaWatch: CNS;Oct2009, Vol. 8 Issue 10, p6 

    The article reports that Bioavail Laboratories International has agreed with Santhera Pharmaceuticals Switzerland to develop and market Santhera's JP-1730/fipamezole, a drug for treating dyskinesia in Parkinson's disease, in Canada and U.S. It notes that their agreement requires Bioavail to make...

  • SEVERE DELIRIUM FOLLOWING SINGLE DOSE OF TRAMADOL. AGRAWAL, AMIT; DIWAN, S. K.; MAHAJAN, RAJESH // Indian Journal of Medical Sciences;Feb2009, Vol. 63 Issue 2, p80 

    A letter to the editor is presented in response to the article on the use of tramadol to treat severe delirium that was published in the previous issue.

  • Delirium. Hendy, Kate // Mental Health Practice;Feb2013, Vol. 16 Issue 5, p8 

    The article reviews the book "Delirium," 2nd edition, by Winnie Manning, Alasdair MacLullich, Meera Agar and Juliet Kelly.

  • Managing information, sharing experiences. McCarthy, Karen // Canadian Nurse;Nov2006, Vol. 102 Issue 9, p2 

    The article discusses various reports published within the issue, including an article about antenatal depression and another on the prevention, assessment and clinical management of delirium.

  • Resolving Conflict and Making Decisions. Glajchen, Myra; Zuckerman, Connie; von Gunten, Charles F. // Journal of Palliative Medicine;Jun2001, Vol. 4 Issue 2, p221 

    Discusses a case report on palliative treatment in a woman diagnosed with terminal delirium and severe cardiomyopathy. Overview of the medical and social histories of the patient; Methods used in resolving the case.

  • Memantine.  // Reactions Weekly;11/2/2013, Issue 1476, p22 

    The article presents a case study of a 98-year-old woman who developed hyperkalaemia after taking memantine for delirium.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics